Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vortioxetine - Lundbeck

X
Drug Profile

Vortioxetine - Lundbeck

Alternative Names: Brintellix; LU-AA21004; LuAA 21004; Trintellix; VORTIDIF; vortioxetine-hydrobromide

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lundbeck A/S
  • Developer Lundbeck A/S; Seoul National University Hospital; Takeda; University of Chicago
  • Class Antidepressants; Anxiolytics; Behavioural disorder therapies; Piperazines; Small molecules; Sulfides
  • Mechanism of Action 5-HT1A serotonin receptor agonists; Serotonin 1B receptor agonists; Serotonin 1D receptor antagonists; Serotonin 3 receptor antagonists; Serotonin 7 receptor antagonists; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Phase II Anxiety disorders; Binge-eating disorder; Bipolar depression
  • Discontinued Attention-deficit hyperactivity disorder; Generalised anxiety disorder

Most Recent Events

  • 18 Oct 2022 Efficacy and adverse events data from a phase III MEMORY trial in Major depressive disorder released by Lundbeck
  • 17 May 2022 Lundbeck A/S terminates a phase III trial in Major depressive disorder in Bulgaria, Latvia, Spain, Colombia, Mexico, Poland, Russia, Ukraine and USA due to early positive results in other study (PO) (NCT05014919)
  • 28 Apr 2022 No recent reports of development identified for phase-I development in Major depressive disorder(In volunteers) in United Kingdom (Sublingual)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top